That starts with innovation.

Boehringer Ingelheim has over 90 years of heritage in managing respiratory disease. Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer.

Partnering in Respiratory Diseases. Ingelheim, Germany and New York, New York, 11 September 2020 – Boehringer Ingelheim and Click Therapeutics today announced they have entered into a collaboration for the development and commercialization of a prescription-based digital therapeutic.

Our growing portfolio of partnerships in respiratory diseases includes collaborations with world-leading academic institutions as well as biotech partnerships and innovative scientific crowdsourcing projects. Boehringer Ingelheim is a global, research-driven pharmaceutical company embracing many cultures and diverse societies. Boehringer Ingelheim has over 95 years of heritage in respiratory disease. Boehringer Ingelheim Venture Fund Scientific Focus The cornerstone of our research into new medicines is focused on those disease areas where we have built significant expertise over time. The company has brought a range of products from its own research & development to market. Reversal of the anticoagulant effects of dabigatran Lung cancer remains the most common cause of cancer deaths worldwide for men, and the second most common for women.

© 2010-2020 Boehringer Ingelheim.

Respiratory. Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer. Pipeline. We want to be part of this transformation. Boehringer Ingelheim is a leader in respiratory medicine with a 100-year history of innovation in this area. Use of this Site is subject to the Terms of Use and Privacy Statement.

A number of these drugs have either achieved blockbuster status with annual sales exceeding one billion US dollars or have blockbuster potential.Diabetes mellitus type II in patients with high cardiovascular riskDiabetes mellitus type II in patients with high cardiovascular risk* These are investigational agents; their safety and efficacy have not yet been established.

At Boehringer Ingelheim, we believe this can be the generation that redefines many cancers as curable diseases.

Boehringer Ingelheim has over 90 years of heritage in managing respiratory disease.

Cardiovascular disease, including heart disease and stroke, is a major global health concern and the leading cause of death and disability worldwide We want to deliver a portfolio of breakthrough medicines that will improve the lives of patients around the word.

Respiratory. We want to deliver a portfolio of breakthrough medicines that will improve the lives of patients around the word. It will utilize cognitive and neurobehavioral mechanisms delivered through Click’s proprietary engagement … All rights reserved. Boehringer Ingelheim is a leader in respiratory medicine with a 100-year history of innovation in this area. About 425 million adult people in the world are living with diabetes, with Type 2 diabetes accounting for 90 percent of all cases

Boehringer Ingelheim is clear about its goals.

Boehringer Ingelheim has over 90 years of heritage in managing respiratory disease. Boehringer Ingelheim Venture Fund Scientific Focus The cornerstone of our research into new medicines is focused on those disease areas where we have built significant expertise over time.

At Boehringer Ingelheim, we believe this can be the generation that redefines many cancers as curable diseases. Boehringer Ingelheim has a rich pipeline showing a number of new molecular entities and a high share of products in late phase development. The company has brought a range of products from its own research & development to market. Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer.

Respiratory. Our growing portfolio of partnerships in respiratory diseases includes collaborations with world-leading academic institutions as well as biotech partnerships and innovative scientific crowdsourcing projects. Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer.

Boehringer Ingelheim is clear about its goals. Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer. in the world are living with diabetes, with Type 2 diabetes accounting for 90% of all casesOur focus is on improving the quality of life of patients suffering from debilitating respiratory diseases and enabling them to maintain a more independent lifeCopyright © 2020 Boehringer Ingelheim (Philippines), Inc. All rights reserved.